Ting Zhao, MD

Molecular Fellow @MGBpathology; Residency/Fellowship @MGHPathology; Stipend/Excellence Awardee @IntSocUropath; Mohanty Awardee @GU_Path_Society #GUpath #MolPath

[Ting Zhao, MD @TingZhaoPathdoc]

🚨🔖Don't miss our new publication in @LIjournal!
🔷Comprehensive Spatial Transcriptomic Profiling of Cribriform, Intraductal, Atypical Intraductal Proliferation, and Ductal Adenocarcinoma of the Prostate
➡️Read here: https://t.co/ACUXXt4g5h

@MGBpathology @IntSocUropath @GU_Path_Society
#GUPath #MolPath #SpatialTranscriptomics #ProstateCancer

[Laboratory Investigation @LIjournal]

New from Laboratory Investigation 🔬 | Using spatial transcriptomics to characterize cribriform, intraductal, atypical intraductal proliferation, and ductal adenocarcinoma of the prostate. @TingZhaoPathdoc

🔗 Zhao et al. Read the article: https://t.co/Y9WBK8I1U1

[GU Pathology Society (GUPS) @GU_Path_Society]

1/7 🗳️ Updates from newsletter

🔸Help shape the future of genitourinary pathology!

GUPS elections- early
Jan 2027- 5 leadership positions open:
🔹 President-Elect (1)
🔹 Education Committee Chair (1)
🔹 Members-at-Large (3)

Interested? 📩 [email protected]
🧵 More updates 👇

[Ting Zhao, MD @TingZhaoPathdoc]

🧬Wondering which sessions to attend on Thursday at #AMP2026?
Check out the exciting plenary sessions below!

@AMPath #MolPath

[Ting Zhao, MD @TingZhaoPathdoc]

🔖Check out the #AMP2026 abstracts published in The Journal of Molecular Diagnostics, highlighting the latest advances in molecular pathology!

💠https://t.co/YMISIdb3mx

@AMPath @JMDiagn
#MolPath

[Association for Molecular Pathology @AMPath]

The #AMP2026 abstract compendium is now available on the @JMDiagn website.

📖 Download it to see what's being presented this week in Seattle: https://t.co/CqkBlzjLId

[GU Pathology Society (GUPS) @GU_Path_Society]

📢 Mark your calendars!

Join #GUPS for our Distinguished Lecture Series featuring Arul M. Chinnaiyan, MD, PhD

Topic: 🧬 Gene Fusions, Oncogenic Drivers, and the Biology of Prostate Cancer: From Discovery to Therapeutic Opportunity

📅 January 7, 2027
⏰ 12:00–1:30 PM EST

[Ting Zhao, MD @TingZhaoPathdoc]

Already in Seattle for #AMP2026? Join us today for educational corporate workshops highlighting the latest technologies and innovations in molecular diagnostics!
@AMPath #MolPath

[Association for Molecular Pathology @AMPath]

Tomorrow at #AMP2026: Corporate Workshop Day! Join us Wednesday for FREE educational workshops exploring emerging technologies and innovations in molecular diagnostics. Open to all attendees and the public. https://t.co/YT2FRatdnm

[Association for Molecular Pathology @AMPath]

The #AMP2026 abstract compendium is now available on the @JMDiagn website.

📖 Download it to see what's being presented this week in Seattle: https://t.co/CqkBlzjLId

[Ting Zhao, MD @TingZhaoPathdoc]

Thank you for this insightful comment, Riham! Argani et al. demonstrated that several "oncocytoid RCCs" arising in survivors of childhood neuroblastoma or medulloblastoma represent ESC RCCs harboring somatic TSC1/TSC2 alterations (PMID: 37522346). The patients with available treatment histories had received chemotherapy, although the specific agents were not detailed. The authors suggested a possible, incompletely characterized tumor-predisposition syndrome. However, investigating whether specific chemotherapeutic agents contribute to the acquisition of somatic TSC1/TSC2 alterations through treatment-associated mutational processes would also be an interesting area.

[Ting Zhao, MD @TingZhaoPathdoc]

10s F with a renal mass. Diagnosis?
#PathX #PathTwitter @MGBpathology

[Ting Zhao, MD @TingZhaoPathdoc]

@patxiqueipo check out the answer I have posted

[Ting Zhao, MD @TingZhaoPathdoc]

30s M with a renal mass. Diagnosis?
#PathX #PathTwitter
@MGBpathology

[Ting Zhao, MD @TingZhaoPathdoc]

Great differentials! EVT and ESC RCC have overlapping morphologic, immunohistochemical, and molecular features. The tumor is CD117+ and CK20���. Taken together with the morphologic features, including intracytoplasmic vacuoles and prominent nucleoli, the tumor is best classified as EVT.

[Ting Zhao, MD @TingZhaoPathdoc]

Great differential! EVT and ESC RCC have overlapping morphologic, immunohistochemical, and molecular features. The tumor is CD117+ and CK20−. Taken together with the morphologic features, including intracytoplasmic vacuoles and prominent nucleoli, the tumor is best classified as EVT.

[Ting Zhao, MD @TingZhaoPathdoc]

@Trantor__ Nice catch! One mitosis was observed in the tumor. Rare mitoses are compatible with the diagnosis and have no proven prognostic meaning to date.

[Ting Zhao, MD @TingZhaoPathdoc]

@DrSteinberg @CD10positive CD117+, CK20-

[Ting Zhao, MD @TingZhaoPathdoc]

@AskMedSphere @MedicalSphereAI This case might be difficult for AI.

[Ting Zhao, MD @TingZhaoPathdoc]

@GuannanTiffany Thank you, Guannan!

[Ting Zhao, MD @TingZhaoPathdoc]

Great thoughts, Sergei! Both are important differential diagnoses, with overlapping morphologic, immunohistochemical, and molecular features. The tumor is CD117+ and CK20−, with retained FH expression. Taken together with the morphologic features, including eosinophilic cytoplasm with intracytoplasmic vacuoles and prominent nucleoli, as well as the additional IHC findings, the tumor is best classified as an EVT.

[Ting Zhao, MD @TingZhaoPathdoc]

@WakagothoK @MGBpathology 👏

[Ting Zhao, MD @TingZhaoPathdoc]

@docvaruna 👍

[Ting Zhao, MD @TingZhaoPathdoc]

@GuannanTiffany @pepeheffernan 🎯

[Ting Zhao, MD @TingZhaoPathdoc]

@MGBpathology Check out the multi-institutional study led by Drs. Jennifer Nguyen @patholojenMD and Ankur Sangoi @slusagar!
▶️ https://t.co/RPmmcyMZzO
#GUpath #MolPath

[Ting Zhao, MD @TingZhaoPathdoc]

Eosinophilic Vacuolated Tumor (EVT) #GUpath #MolPath
🔷Solid/nested with eosinophilic cytoplasm containing intracytoplasmic vacuoles, and prominent nucleoli
🔷IHC: PAX8+, CD117+, CD10+, cathepsin K+ (~75–80%), GPNMB+, CD56+ (~98%); CK7 and CK20- or rare/focal (PMID: 34521993, 39033022, 42986404)
🔷🧬Molecular: TSC1, TSC2, or MTOR alterations with mTORC1 activation; mostly somatic, rarely associated with germline TSC1/TSC2 alterations (tuberous sclerosis complex), as in this case
🔷Prognosis: Generally indolent; lymph node metastasis rarely reported (PMID: 40474716, 41171101)